Targets to retard the progression of diabetic nephropathy
Authors:
- Mark E. CooperMCMark E. Cooper
- Karin Jandeleit-DahmKJKarin Jandeleit-Dahm
- Merlin C. ThomasMTMerlin C. Thomas
- 1 October 2005
- journal article
- conference paper
- Published by Elsevier in Kidney International
- Vol. 68 (4) , 1439-1445
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Imatinib Attenuates Diabetic Nephropathy in Apolipoprotein E-Knockout MiceJournal of the American Society of Nephrology, 2005
- AGEs activate mesangial TGF-β–Smad signaling via an angiotensin II type I receptor interactionKidney International, 2004
- Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trialKidney International, 2004
- Biochemistry and molecular cell biology of diabetic complicationsNature, 2001
- Global and societal implications of the diabetes epidemicNature, 2001
- Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patientsNephrology Dialysis Transplantation, 2001
- A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR)Kidney International, 1998
- Reversal of Anemia by Erythropoietin Therapy Retards the Progression of Chronic Renal Failure, Especially in Nondiabetic PatientsNephron, 1997
- Prevalence of microalbuminuria, arterial hypertension, retinopathy, and neuropathy in patients with insulin dependent diabetesBMJ, 1988
- Glomerular response mechanisms to glycemie changes in insulin–dependent diabeticsKidney International, 1987